Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

The suppression of thymic stromal lymphopoietin expression by selenium.

Moon PD, Kim HM.

Amino Acids. 2012 Aug;43(2):999-1004. doi: 10.1007/s00726-011-1156-z.

PMID:
22086213
2.

Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity.

Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L.

J Biol Chem. 2011 Jul 1;286(26):23591-9. doi: 10.1074/jbc.M111.237123.

3.

Myeloid cell population dynamics in healthy and tumor-bearing mice.

Ueha S, Shand FH, Matsushima K.

Int Immunopharmacol. 2011 Jul;11(7):783-8. doi: 10.1016/j.intimp.2011.03.003. Review.

PMID:
21406269
4.

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Dinarello CA.

Blood. 2011 Apr 7;117(14):3720-32. doi: 10.1182/blood-2010-07-273417. Review.

5.

IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA.

Eur J Immunol. 2010 Dec;40(12):3347-57. doi: 10.1002/eji.201041037.

6.

Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment.

van der Meij BS, Langius JA, Smit EF, Spreeuwenberg MD, von Blomberg BM, Heijboer AC, Paul MA, van Leeuwen PA.

J Nutr. 2010 Oct;140(10):1774-80. doi: 10.3945/jn.110.121202.

7.

Impaired immune function: an early marker for cancer cachexia.

Faber J, Vos AP, Kegler D, Argilés J, Laviano A, Garssen J, Van Helvoort A.

Oncol Rep. 2009 Dec;22(6):1403-6.

PMID:
19885593
8.
9.

Subsets of myeloid-derived suppressor cells in tumor-bearing mice.

Youn JI, Nagaraj S, Collazo M, Gabrilovich DI.

J Immunol. 2008 Oct 15;181(8):5791-802.

10.

Effect of selenium on pancreatic proinflammatory cytokines in streptozotocin-induced diabetic mice.

Zeng J, Zhou J, Huang K.

J Nutr Biochem. 2009 Jul;20(7):530-6. doi: 10.1016/j.jnutbio.2008.05.012.

PMID:
18789669
11.

Cachexia: a new definition.

Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD.

Clin Nutr. 2008 Dec;27(6):793-9. doi: 10.1016/j.clnu.2008.06.013.

PMID:
18718696
12.

Mechanisms by which selenium influences immune responses.

Hoffmann PR.

Arch Immunol Ther Exp (Warsz). 2007 Sep-Oct;55(5):289-97. Review.

PMID:
18219759
13.

Mechanism and therapeutic reversal of immune suppression in cancer.

Herber DL, Nagaraj S, Djeu JY, Gabrilovich DI.

Cancer Res. 2007 Jun 1;67(11):5067-9. No abstract available.

15.

Cellular immune response is not associated with incident cancer or total mortality: a prospective follow-up.

Roth MJ, Qiao YL, Abnet CC, Zhang YH, Dawsey SM, Dong ZW, Taylor PR.

Eur J Cancer Prev. 2006 Dec;15(6):548-50.

PMID:
17106336
16.

Review article: immune suppression and colorectal cancer.

Evans C, Dalgleish AG, Kumar D.

Aliment Pharmacol Ther. 2006 Oct 15;24(8):1163-77. Review.

17.

The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.

Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI.

Genes Dev. 2006 Sep 15;20(18):2527-38.

18.

Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency.

Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K, Bezrodnik L, Teper A, Gaillard M, Heinrich J, Krensky AM, Rosenfeld RG, Lewis DB.

J Immunol. 2006 Sep 1;177(5):2770-4.

19.
20.

Regulatory T cells in cancer.

Beyer M, Schultze JL.

Blood. 2006 Aug 1;108(3):804-11. Review.

Supplemental Content

Support Center